These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25394107)

  • 1. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults.
    Gatell JM; Arribas JR; Lázaro P; Blasco A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19603. PubMed ID: 25394107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
    Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Blasco AJ; Llibre JM; Berenguer J; González-García J; Knobel H; Lozano F; Podzamczer D; Pulido F; Rivero A; Tuset M; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2015 Mar; 33(3):156-65. PubMed ID: 25175171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Crespo M; Domingo P; Estrada V; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; de la Torre J; Tuset M; Gatell JM
    Enferm Infecc Microbiol Clin; 2017 Feb; 35(2):88-99. PubMed ID: 27459919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
    Blasco AJ; Llibre JM; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):568-78. PubMed ID: 23969276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Berenguer J; Rivero A; Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; Lázaro P; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Tuset M; Gatell JM;
    Enferm Infecc Microbiol Clin; 2016; 34(6):361-71. PubMed ID: 26321131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
    Blasco AJ; Arribas JR; Clotet B; Domingo P; González-García J; López-Bernaldo JC; Llibre JM; Lozano F; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM
    Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):721-30. PubMed ID: 22014894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.
    Gatell Artigas JM; Arribas López JR; Lázaro Y de Mercado P; Blasco Bravo AJ
    Enferm Infecc Microbiol Clin; 2016; 34(7):427-30. PubMed ID: 25749416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.
    Pérez-Molina JA; Martínez E; Blasco AJ; Arribas JR; Domingo P; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Mariño A; Miró JM; Moreno S; Negredo E; Pulido F; Rubio R; Santos J; de la Torre J; Tuset M; von Wichmann MA; Gatell JM
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Mar; 37(3):151-159. PubMed ID: 29884455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Asensi V; Crespo M; Domingo P; Iribarren JA; Lázaro P; López-Aldeguer J; Lozano F; Martínez E; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; Santos J; de la Torre J; Tuset M; Gatell JM
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 May; 36(5):268-276. PubMed ID: 28532596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
    Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
    HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain.
    Davis AE; Brogan AJ; Goodwin B; Nocea G; Lozano V
    HIV Clin Trials; 2017; 18(5-6):214-222. PubMed ID: 29210626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
    Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
    Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
    Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.